Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck
G. Catimel(Centre Léon Bérard), Jan B. Vermorken(University of Antwerp), T. Cerny(Institut Jules Bordet), Susan S. Kaplan(Western Infirmary), W ten Bokkel Huinink(European Organisation for Research and Treatment of Cancer), N. Pavlidis, Cristiana Sessa(Institute of Oncology Research), Martine Piccart(Université Libre de Bruxelles), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), M. Clavel(Centre Léon Bérard), S.B. Kaye(Western Infirmary), P Siegenthaler(Institut Jules Bordet), H. Franklin(European Organisation for Research and Treatment of Cancer), Axel‐R. Hanauske(TUM Klinikum), Jaap Verweij(Deutz (Germany)), J. Wanders(Eisai (United Kingdom)), H.H. Hansen, A.T. van Oosterom(Fondazione Vincenzo Pansadoro), Vera Mattijssen(Radboud University Nijmegen), M. Marty(Hôpital Saint-Louis), N Le Bail
Cited by 259
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
|New England Journal of Medicine|2008|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k